Johnson & Johnson (JNJ) Position Lowered by Fulton Bank N.A.

Fulton Bank N.A. lowered its position in Johnson & Johnson (NYSE:JNJ) by 2.5% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 69,716 shares of the company’s stock after selling 1,768 shares during the period. Johnson & Johnson comprises 0.7% of Fulton Bank N.A.’s holdings, making the stock its 28th largest position. Fulton Bank N.A.’s holdings in Johnson & Johnson were worth $9,064,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in JNJ. Pachira Investments Inc. increased its holdings in Johnson & Johnson by 12.2% during the 1st quarter. Pachira Investments Inc. now owns 4,424 shares of the company’s stock worth $551,000 after purchasing an additional 480 shares in the last quarter. Schaper Benz & Wise Investment Counsel Inc. WI increased its holdings in Johnson & Johnson by 0.5% during the 1st quarter. Schaper Benz & Wise Investment Counsel Inc. WI now owns 114,681 shares of the company’s stock worth $14,283,000 after purchasing an additional 544 shares in the last quarter. Cedar Wealth Management LLC increased its holdings in Johnson & Johnson by 5.3% during the 1st quarter. Cedar Wealth Management LLC now owns 3,294 shares of the company’s stock worth $410,000 after purchasing an additional 167 shares in the last quarter. Usca Ria LLC increased its holdings in Johnson & Johnson by 4.7% during the 1st quarter. Usca Ria LLC now owns 49,607 shares of the company’s stock worth $6,179,000 after purchasing an additional 2,244 shares in the last quarter. Finally, Willingdon Wealth Management increased its holdings in Johnson & Johnson by 11.8% during the 1st quarter. Willingdon Wealth Management now owns 12,958 shares of the company’s stock worth $1,614,000 after purchasing an additional 1,372 shares in the last quarter. Institutional investors and hedge funds own 65.70% of the company’s stock.

A number of equities analysts have issued reports on the company. Zacks Investment Research cut Johnson & Johnson from a “buy” rating to a “hold” rating in a report on Tuesday, December 12th. Citigroup assumed coverage on shares of Johnson & Johnson in a research note on Monday, September 25th. They set a “neutral” rating and a $140.00 price objective for the company. BMO Capital Markets restated a “positive” rating and set a $152.00 price objective (up from $145.00) on shares of Johnson & Johnson in a research note on Wednesday, October 18th. Jefferies Group increased their price objective on shares of Johnson & Johnson from $157.00 to $160.00 and gave the stock a “buy” rating in a research note on Monday, October 16th. Finally, Royal Bank of Canada increased their price objective on shares of Johnson & Johnson from $144.00 to $147.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 18th. Four equities research analysts have rated the stock with a sell rating, seven have assigned a hold rating and eleven have issued a buy rating to the company. The company has a consensus rating of “Hold” and an average target price of $145.04.

Shares of Johnson & Johnson (JNJ) opened at $141.80 on Tuesday. Johnson & Johnson has a one year low of $110.76 and a one year high of $144.35. The stock has a market cap of $382,721.66, a PE ratio of 19.95, a P/E/G ratio of 2.90 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.32 and a debt-to-equity ratio of 0.36.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $1.80 by $0.10. Johnson & Johnson had a net margin of 21.28% and a return on equity of 27.38%. The business had revenue of $19.65 billion during the quarter, compared to the consensus estimate of $19.29 billion. During the same period last year, the business posted $1.68 EPS. Johnson & Johnson’s revenue was up 10.3% on a year-over-year basis. equities analysts predict that Johnson & Johnson will post 7.28 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which was paid on Tuesday, December 12th. Investors of record on Tuesday, November 28th were paid a $0.84 dividend. The ex-dividend date of this dividend was Monday, November 27th. This represents a $3.36 annualized dividend and a yield of 2.37%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 58.33%.

ILLEGAL ACTIVITY NOTICE: This report was first posted by Sports Perspectives and is owned by of Sports Perspectives. If you are accessing this report on another website, it was stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this report can be accessed at https://sportsperspectives.com/2017/12/19/johnson-johnson-jnj-position-lowered-by-fulton-bank-n-a.html.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply